Just to add to that .... the CEO mentioned in the December Redchip presentation that IMC will be focusing on the liver enzymes (liver injury) as well as blood glucose levels and insulin resistance from the NASH trial results. If there is substantial, consistent & statistically significant improvement in the blood glucose & insulin resistance readings over the course of treatment, this may open up other opportunities in the diabetes treatment market ... i.e. reduce insulin requirements for type-1 patients & potentially stall the progression of pre-diabetes into full blown type-2 ... all with a safe oral treatment.
If the fat fraction objective is not met, other opportunities outside of NASH could arise.
IMO... GLTAH
Just to add to that .... the CEO mentioned in the December...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.9¢ |
Change
-0.006(5.71%) |
Mkt cap ! $22.57M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 9.9¢ | $32.90K | 328.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 27022 | 9.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 100000 | 1 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| IMC (ASX) Chart |